Kenneth I Ataga

List of Publications by Year
in descending order

129	7,279	76196	60497
papers	citations	40 h-index	81 g-index

134	134	134	5111
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	3.8	741
2	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 429-439.	13.9	599
3	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	13.9	401
4	The risks and benefits of longâ€term use of hydroxyurea in sickle cell anemia: A 17.5 year followâ€up. American Journal of Hematology, 2010, 85, 403-408.	2.0	385
5	Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British Journal of Haematology, 2006, 134, 109-115.	1.2	274
6	Factors associated with survival in a contemporary adult sickle cell disease cohort. American Journal of Hematology, 2014, 89, 530-535.	2.0	235
7	Renal abnormalities in sickle cell disease. , 2000, 63, 205-211.		210
8	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	2.5	197
9	Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood, 2008, 111, 3991-3997.	0.6	193
10	Î²â€Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. British Journal of Haematology, 2007, 139, 3-13.	1.2	188
11	Hypercoagulability in sickle cell disease: a curious paradox. American Journal of Medicine, 2003, 115, 721-728.	0.6	185
12	Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vasoâ€occlusive crises in patients with sickle cell disease: a phase III randomized, placeboâ€controlled, doubleâ€blind study of the gardos channel blocker senicapoc (ICAâ€17043). British Journal of Haematology, 2011, 153, 92-104.	1.2	185
13	Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2001, 286, 2099.	3.8	173
14	Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem. Hematology American Society of Hematology Education Program, 2007, 2007, 91-96.	0.9	166
15	Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica, 2008, 93, 20-26.	1.7	162
16	Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica, 2009, 94, 1481-1484.	1.7	142
17	Pulmonary hypertension in sickle cell disease. American Journal of Medicine, 2004, 117, 665-669.	0.6	140
18	Biologically Active CD40 Ligand Is Elevated in Sickle Cell Anemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1626-1631.	1.1	138

#	Article	IF	Citations
19	Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology, 2010, 149, 426-435.	1.2	114
20	The glomerulopathy of sickle cell disease. American Journal of Hematology, 2014, 89, 907-914.	2.0	100
21	Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Reviews, 2016, 30, 245-256.	2.8	99
22	Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica, 2017, 102, 626-636.	1.7	97
23	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Advances, 2019, 3, 3867-3897.	2.5	87
24	Association of Coagulation Activation with Clinical Complications in Sickle Cell Disease. PLoS ONE, 2012, 7, e29786.	1.1	85
25	A potent oral Pâ€selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. American Journal of Hematology, 2012, 87, 536-539.	2.0	72
26	Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood, 2019, 133, 615-617.	0.6	71
27	Hemostatic abnormalities in sickle cell disease. Current Opinion in Hematology, 2013, 20, 472-477.	1.2	70
28	Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrology Dialysis Transplantation, 2014, 29, 1211-1218.	0.4	64
29	A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal of Hematology and Oncology, 2013, 6, 17.	6.9	62
30	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2021, 8, e323-e333.	2.2	61
31	Dose-Escalation Study of ICA-17043 in Patients with Sickle Cell Disease. Pharmacotherapy, 2006, 26, 1557-1564.	1.2	51
32	Phase I study of eptifibatide in patients with sickle cell anaemia. British Journal of Haematology, 2007, 139, 612-620.	1.2	51
33	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opinion on Investigational Drugs, 2009, 18, 231-239.	1.9	51
34	Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fmsâ€like tyrosine kinaseâ€1. European Journal of Haematology, 2010, 85, 257-263.	1.1	51
35	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood, 2019, 133, 2529-2541.	0.6	51
36	Bone Marrow Necrosis in Sickle Cell Disease: A Description of Three Cases and a Review of the Literature. American Journal of the Medical Sciences, 2000, 320, 342-347.	0.4	50

#	Article	IF	Citations
37	Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease. American Journal of the Medical Sciences, 2010, 339, 266-269.	0.4	49
38	Fibronectin bridges monocytes and reticulocytes via integrin Î±4Î²1. British Journal of Haematology, 2008, 141, 872-881.	1.2	44
39	Care Seeking for Pain in Young Adults with Sickle Cell Disease. Pain Management Nursing, 2014, 15, 324-330.	0.4	43
40	Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease. American Journal of Hematology, 2015, 90, 691-695.	2.0	43
41	Refining the value of secretory phospholipase <scp>A</scp>₂ as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (<scp>PROACTIVE</scp>). British Journal of Haematology, 2012, 157, 627-636.	1.2	42
42	Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. Blood, 2010, 115, 2014-2020.	0.6	41
43	A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thrombosis Research, 2013, 132, 341-345.	0.8	38
44	Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study. American Journal of Kidney Diseases, 2019, 74, 47-55.	2.1	37
45	Renal cell carcinoma. Current Opinion in Oncology, 2000, 12, 260-264.	1.1	36
46	The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease. Journal of Clinical Pharmacology, 2005, 45, 434-445.	1.0	35
47	Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. British Journal of Haematology, 2011, 155, 263-267.	1.2	34
48	Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis. PLoS ONE, 2020, 15, e0229959.	1.1	32
49	A doseâ€escalation phase IIa study of 2,2â€dimethylbutyrate (HQKâ€1001), an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology, 2013, 88, E255-60.	2.0	31
50	Estimated pulmonary artery systolic pressure and sickle cell disease: a metaâ€analysis and systematic review. British Journal of Haematology, 2015, 170, 416-424.	1.2	31
51	A phase 1/2 trial of HQKâ€1001, an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology, 2012, 87, 1017-1021.	2.0	30
52	NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. PLoS ONE, 2017, 12, e0171067.	1.1	30
53	Drug Therapies for the Management of Sickle Cell Disease. F1000Research, 2020, 9, 592.	0.8	29
54	Novel therapies in sickle cell disease. Hematology American Society of Hematology Education Program, 2009, 2009, 54-61.	0.9	28

#	Article	IF	Citations
55	The trials and hopes for drug development in sickle cell disease. British Journal of Haematology, 2015, 170, 768-780.	1.2	27
56	Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia. PLoS ONE, 2016, 11, e0162652.	1.1	27
57	The nephropathy of sickle cell trait and sickle cell disease. Nature Reviews Nephrology, 2022, 18, 361-377.	4.1	26
58	Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. Blood Advances, 2018, 2, 3035-3044.	2.5	25
59	Preliminary Validity and Reliability of the Sickle Cell Disease Health-Related Stigma Scale. Issues in Mental Health Nursing, 2012, 33, 363-369.	0.6	24
60	Coagulation activation in sickle cell trait: an exploratory study. British Journal of Haematology, 2015, 171, 638-646.	1.2	24
61	Association of soluble fmsâ€like tyrosine kinaseâ€1 with pulmonary hypertension and haemolysis in sickle cell disease. British Journal of Haematology, 2011, 152, 485-491.	1.2	21
62	Effect of reninâ€angiotensinâ€aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease. British Journal of Haematology, 2019, 184, 246-252.	1.2	20
63	Monocytosis is associated with hemolysis in sickle cell disease. Hematology, 2015, 20, 593-597.	0.7	19
64	Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia. Current Molecular Medicine, 2008, 8, 639-645.	0.6	18
65	Hemodynamic Characteristics and Predictors of Pulmonary Hypertension in Patients With Sickle Cell Disease. American Journal of Cardiology, 2012, 109, 1353-1357.	0.7	17
66	The acute chest syndrome of sickle cell disease. Expert Opinion on Pharmacotherapy, 2013, 14, 991-999.	0.9	16
67	Machine Learning to Quantitate Neutrophil NETosis. Scientific Reports, 2019, 9, 16891.	1.6	16
68	SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. Blood, 2016, 128, 1-1.	0.6	16
69	Haemoglobin response to senicapoc in patients with sickle cell disease: a reâ€analysis of the Phase III trial. British Journal of Haematology, 2021, 192, e129-e132.	1.2	15
70	Renal protection by atorvastatin in a murine model of sickle cell nephropathy. British Journal of Haematology, 2018, 181, 111-121.	1.2	14
71	Decades after the cooperative study: A reâ€examination of systemic blood pressure in sickle cell disease. American Journal of Hematology, 2012, 87, E65-8.	2.0	13
72	Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. Pediatric Blood and Cancer, 2018, 65, e26993.	0.8	13

#	Article	IF	Citations
73	Advances in new drug therapies for the management of sickle cell disease. Expert Opinion on Orphan Drugs, 2018, 6, 329-343.	0.5	13
74	Systemic Blood Pressure Is Associated with Anemia and Placenta Growth Factor In Sickle Cell Anemia. Blood, 2010, 116, 2644-2644.	0.6	13
75	Establishing sickle cell diagnostics and characterizing a paediatric sickle cell disease cohort in Malawi. British Journal of Haematology, 2016, 174, 325-329.	1.2	12
76	Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality. British Journal of Haematology, 2019, 186, 900-907.	1.2	12
77	Endothelin-1 Is Associated with Albuminuria and Measures of Vascular Endothelial Dysfunction in Sickle Cell Anemia. Blood, 2015, 126, 983-983.	0.6	12
78	Pulmonary hypertension in sickle cell disease: diagnosis and management. Hematology American Society of Hematology Education Program, 2014, 2014, 425-431.	0.9	11
79	Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. Haematologica, 2021, 106, 1749-1753.	1.7	11
80	Longitudinal study of echocardiographyâ€derived tricuspid regurgitant jet velocity in sickle cell disease. British Journal of Haematology, 2013, 162, 836-841.	1.2	10
81	Thrombospondinâ€1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. American Journal of Hematology, 2017, 92, E31-E34.	2.0	10
82	Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell disease. American Journal of Hematology, 2015, 90, E223-4.	2.0	9
83	Plasma metabolomics analysis in sickle cell disease patients with albuminuria â€“ an exploratory study. British Journal of Haematology, 2019, 185, 620-623.	1.2	9
84	The Relationship of Pulmonary Hypertension and Survival in Sickle Cell Disease.. Blood, 2004, 104, 1665-1665.	0.6	9
85	A Phase I Single Ascending Dose Study Of NKTT120 In Stable Adult Sickle Cell Patients. Blood, 2013, 122, 977-977.	0.6	9
86	Using Machine Learning to Predict Early Onset Acute Organ Failure in Critically Ill Intensive Care Unit Patients With Sickle Cell Disease: Retrospective Study. Journal of Medical Internet Research, 2020, 22, e14693.	2.1	9
87	High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia. Haematologica, 2020, 106, 295-298.	1.7	9
88	A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease.. Blood, 2006, 108, 685-685.	0.6	8
89	Multiple myeloma in the breast. , 1999, 61, 203-204.		7
90	Longitudinal study of glomerular hyperfiltration and normalization of estimated glomerular filtration in adults with sickle cell disease. British Journal of Haematology, 2021, 195, 123-132.	1.2	7

#	Article	IF	Citations
91	Microangiopathic hemolytic anemia associated with metastatic breast carcinoma. , 1999, 61, 254-255.		6
92	A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease. American Journal of Hematology, 2019, 94, E299-E301.	2.0	6
93	Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia. Blood Advances, 2021, 5, 89-98.	2.5	6
94	Albuminuria Is Associated with Endothelial Dysfunction in Sickle Cell Disease. Blood, 2015, 126, 2186-2186.	0.6	6
95	Hypercoagulability in Sickle Cell Disease: The Importance of the Cellular Component of Blood. Blood, 2014, 124, 4060-4060.	0.6	5
96	Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis. Blood Advances, 2022, 6, 4461-4470.	2.5	5
97	Does hydroxyurea prevent pulmonary complications of sickle cell disease?. Hematology American Society of Hematology Education Program, 2014, 2014, 432-437.	0.9	4
98	Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease. American Journal of Hematology, 2018, 93, E99-E101.	2.0	4
99	Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. International Journal of Public Health, 2021, 66, 629338.	1.0	4
100	Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study. British Journal of Haematology, 2021, 194, e71-e73.	1.2	4
101	Markers of Coagulation Activation and Inflammation in Sickle Cell Disease and Sickle Cell Trait. Blood, 2008, 112, 4813-4813.	0.6	4
102	Tetrahydrobiopterin (6R-BH4): Novel Therapy for Endothelial Dysfunction in Sickle Cell Disease. Blood, 2008, 112, lba-5-lba-5.	0.6	4
103	Clinical Characteristics Associated with Survival in Adult Sickle Cell Disease. Blood, 2012, 120, 3229-3229.	0.6	4
104	Sickle Cell Nephropathy: Current Understanding of the Presentation, Diagnostic and Therapeutic Challenges. , 2018, , .		3
105	Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.. Blood, 2004, 104, 103-103.	0.6	3
106	Progression of Pulmonary Hypertension in Patients with Sickle Cell Disease.. Blood, 2005, 106, 3187-3187.	0.6	3
107	Increased Red Cell Phosphatidylserine Exposure Correlates with Enhanced Thrombin Generation In Sickle Trait Patients with End Stage Renal Disease. Blood, 2010, 116, 2665-2665.	0.6	3
108	Progression of Chronic Kidney Disease in Sickle Cell Disease. Blood, 2016, 128, 1323-1323.	0.6	3

#	Article	IF	Citations
109	Sickle Cardiomyopathy. JACC: Cardiovascular Imaging, 2016, 9, 253-254.	2.3	2
110	Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia. Blood, 2010, 116, 943-943.	0.6	2
111	Lack of Difference in Hepcidin Levels in Sickle Cell Anemia and Sickle Cell Beta Thalassemia. Blood, 2015, 126, 4591-4591.	0.6	2
112	Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease. Blood, 2016, 128, 2478-2478.	0.6	2
113	Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease. EBioMedicine, 2017, 24, 26-27.	2.7	1
114	Using machine learning to predict rapid decline of kidney function in sickle cell anemia. EJHaem, 2021, 2, 257-260.	0.4	1
115	A pilot study of the effect of rivaroxaban in sickle cell anemia. Transfusion, 2021, 61, 1694-1698.	0.8	1
116	Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results. British Journal of Haematology, 2021, 194, 469-473.	1.2	1
117	A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease. Blood, 2011, 118, 1066-1066.	0.6	1
118	Establishing Sickle Cell Diagnostics and Characterizing a Pediatric Sickle Cell Disease Cohort in Malawi. Blood, 2015, 126, 2070-2070.	0.6	1
119	Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia. Blood, 2019, 134, 2308-2308.	0.6	1
120	Hemostatic Aspects of Sickle Cell Disease. , 2019, , 819-842.		0
121	Longitudinal Study of Echocardiographically-Derived Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease. Blood, 2011, 118, 2121-2121.	0.6	0
122	A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	0
123	A Pilot Study of Eptifibatide for Treatment of Acute Pain Episodes in Sickle Cell Disease.. Blood, 2012, 120, 2102-2102.	0.6	0
124	Hydroxyurea Is Associated with Lower Prevalence of Albuminuria in Adults with Sickle Cell Disease. Blood, 2012, 120, 3211-3211.	0.6	0
125	Hemostatic Aspects of Sickle Cell Disease. , 2013, , 771-785.		0
126	HemobloginA2 Levels Associate with Lower ESA-Dose in African-Americans with Sickle Cell Trait and End-Stage Kidney Disease. Blood, 2015, 126, 3407-3407.	0.6	0

#	Article	IF	Citations
127	Nutritional Status and Hydroxyurea Use Among Children with Sickle Cell Disease in Malawi. Blood, 2016, 128, 2499-2499.	0.6	0
128	Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia. Blood, 2016, 128, 2491-2491.	0.6	0
129	Early Renal Disease in Children with Sickle Cell Disease from Malawi. Blood, 2016, 128, 1316-1316.	0.6	0